Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Chase Investment Counsel Corp

Chase Investment Counsel Corp lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 93,601 shares of the biopharmaceutical company’s stock after purchasing an additional 2,264 shares during the quarter. Halozyme Therapeutics comprises 1.8% of Chase Investment Counsel Corp’s investment portfolio, making the stock its 20th biggest position. Chase Investment Counsel Corp’s holdings in Halozyme Therapeutics were worth $5,357,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. GAMMA Investing LLC grew its position in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $49,000. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the third quarter valued at about $65,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Down 2.4 %

Shares of NASDAQ:HALO opened at $59.61 on Wednesday. The firm has a 50 day simple moving average of $56.53 and a 200-day simple moving average of $53.18. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $7.58 billion, a PE ratio of 19.74, a P/E/G ratio of 0.56 and a beta of 1.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HALO shares. Morgan Stanley lifted their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright upped their price target on Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, TD Cowen lifted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 70,000 shares of company stock valued at $4,042,500 over the last ninety days. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.